Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Eclinical deterioration Edeath or ventilation E

COVID 19 hospitalized meta-analysis

RCTbaricitinibplaceboCOVID 19 hospitalizedlow
764/761 suggested -39% 23% 11%
STOP-COVID (Guimarães)
RCTtofacitinibplaceboCOVID 19 hospitalizedlow
144/145 conclusif -46% -41% demonstrated-33%
ACTT-2 (Kalil)
RCTbaricitinibplaceboCOVID 19 hospitalizedlow
515/518 conclusif -32% demonstrated14% -28%

COVID 19 all comers meta-analysis

RCTbaricitinibstandard of careCOVID 19 all comerssome concern
4148/4008 conclusif demonstrated-12% -9%

COVID-19 severe or critically meta-analysis

COV-BARRIER (critically ill)
RCTbaricitinibplaceboCOVID-19 severe or criticallylow
51/50 suggested -41% 168%
Cao RCTruxolitinibvitamin CCOVID-19 severe or criticallysome concern
21/21 suggested -76% 60% -80%
5 studies excluded by filtering options (2 RCT / 3 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).